Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Medicine & Life Sciences

• cabozantinib 100%
• Everolimus 77%
• Renal Cell Carcinoma 59%
• Protein-Tyrosine Kinases 17%
• Survival 13%
• Safety 11%
• Radiology 9%
• Progression-Free Survival 8%
• Clear-cell metastatic renal cell carcinoma 7%
• Therapeutics 6%
• Aspiration Pneumonia 6%
• Aspergillosis 5%
• Advisory Committees 5%
• Random Allocation 4%
• Standard of Care 4%
• Intention 4%
• Hyperglycemia 4%
• Fatigue 4%
• Anemia 4%
• Diarrhea 3%
• Disease Progression 3%
• Hypertension 3%
• Pharmaceutical Preparations 1%
• Neoplasms 1%